Stay up to date on the best new restaurants, recent openings, and the biggest dining updates across Greater Boston's food ...

JetBlue has a new Boston-themed plane. The new Boston-themed plane is set to be unveiled on Friday during a ceremony at Logan Airport in Boston. The new JetBlue plane is an Airbus A320-232. Do you ...

Brian McGrory led the news organization for a decade until he departed in early 2023. By Katie Robertson The Boston Globe said on Monday that a former longtime editor, Brian McGrory, would return to ...

Boston Mayor Michelle Wu said the city is extending a program that aims to revitalize the downtown by converting vacant office buildings into housing projects for another 12 months. The city’s office ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

JPMorgan Chase & Co. plans to move its Boston offices to the new South Station Tower — and join the rarefied ranks of companies that have stamped their names on the city’s skyline. In a sign of its ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Jeffrey is a freelance features writer at Collider. He is an MPA-accredited entertainment journalist and a Tomatometer-approved critic based in the LA area. He graduated from the University of Texas ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...